Fundraising FoxDialectic Therapeutics
San Antonio, US · Founded 2018 · Delaware corporation
Find your way into Dialectic Therapeutics
Sign up to see every warm intro you have to Dialectic Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dialectic Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Founders & leadership
Dialectic Therapeutics was founded in 2018 by Daohong Zhou, Guangrong Zheng, and John D. Harkey Jr., JD, MBA.
Funding
SEC filings, press & company announcements$8.8M disclosed across 3 of 4 rounds · 2018–2020
- Undisclosed amountSeedFeb 2020Source ↗
▶$6.3MraisedFeb 2021 · 27 investors · BiotechnologyRule 506(b)
- David GenecovExecutive Officer, Director
- John D. HarkeyDirector
- Daohong ZhouDirector
- Joshua SillsExecutive Officer
- Robert HromasDirector
- Offering amount
- $6.3M
- Amount sold
- $6.3M
- Minimum investment
- $50K
- Proceeds to insiders
- $100K
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$500KraisedOct 2020 · 12 investors · BiotechnologyRule 506(b)
- John D. HarkeyDirector
- David GenecovExecutive Officer, Director
- Daohong ZhouDirector
- Robert HromasDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $2.5K
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$2MraisedNov 2018 · 2 investors · BiotechnologyRule 506(b)
- David GenecovDirector
- John D. HarkeyDirector
- Daohong ZhouExecutive Officer, Director
- Robert HromasExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $2M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Dialectic Therapeutics.
In the news
Frequently asked questions
- What does Dialectic Therapeutics do?
- Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
- Who founded Dialectic Therapeutics?
- Dialectic Therapeutics was founded by Daohong Zhou, Guangrong Zheng, John D. Harkey Jr., JD, MBA in 2018.
- How much funding has Dialectic Therapeutics raised?
- Dialectic Therapeutics has disclosed $8.8M raised across 3 of its 4 known rounds.
- Where is Dialectic Therapeutics headquartered?
- Dialectic Therapeutics is headquartered in San Antonio, US.